Results 221 to 230 of about 132,571 (292)
Immune Checkpoint Inhibitors and Cardiovascular Adverse Events
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna+4 more
wiley +1 more source
Abstract Aims Hypertrophic cardiomyopathy (HCM) is a rare genetic heart disease characterized by a limited patient population and scarce research and treatment resources. This study aimed to identify HCM‐associated proteins by integrating cardiac tissue data from the Gene Expression Omnibus (GEO) database with the latest protein quantitative trait ...
Bo Li, Xu Zhao, Yan Ding, Yi Zhang
wiley +1 more source
Short- and mid-term outcomes of surgical repair of acute type A aortic dissection and concomitant coronary artery bypass grafting or extracorporeal membrane oxygenation support. [PDF]
Zhang D+8 more
europepmc +1 more source
Effect of α-hANP on coronary circulation and myocardial contractility
Akinori Shimizu
openalex +2 more sources
BUN‐to‐ALB ratio as an effective predictor of 30 day mortality in ADHF patients in eastern China
Abstract Aims The blood urea nitrogen‐to‐albumin ratio (BAR) is considered a potential indicator for assessing the poor prognosis of heart failure (HF). However, its prognostic value for Chinese patients with acute decompensated HF (ADHF) remains unclear.
Xin Huang+8 more
wiley +1 more source
Abstract Aims Right ventricular (RV) remodelling, a progressive condition characterized by maladaptive cardiac structural and functional changes, primarily results from prolonged pressure overload in patients with pulmonary hypertension (PH). Accurate, universal and easy‐to‐use biomarkers for assessing the severity of RV remodelling are lacking.
Xuenan Wang+5 more
wiley +1 more source
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira+26 more
wiley +1 more source